{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:33:32Z","timestamp":1792082012854,"version":"4.4.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0080890","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T16:21:18Z","timestamp":1386346878000},"page":"e80890","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"8","author":[{"given":"Zhiyun","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1359\/jbmr.1999.14.7.1061","article-title":"New developments in the pathogenesis and treatment of steroid-induced osteoporosis","volume":"14","author":"SC Manolagas","year":"1999","journal-title":"J Bone Miner Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00002281-200203000-00008","article-title":"Cost of illness studies in rheumatic diseases","volume":"14","author":"B Fautrel","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","first-page":"1495","article-title":"Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases","volume":"24","author":"AC Verhoeven","year":"1997","journal-title":"J Rheumatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/34.8.742","article-title":"The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women","volume":"34","author":"F Pons","year":"1995","journal-title":"Br J Rheumatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/BF02231770","article-title":"Bone mineral content of the third lumbar vertebra during 18 months of prednisolone treatment for giant cell arteritis","volume":"12","author":"E Nordborg","year":"1993","journal-title":"Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"TP van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/qjmed\/hci029","article-title":"A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids","volume":"98","author":"TP van Staa","year":"2005","journal-title":"QJM"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard.51.6.826","article-title":"Bone mass in patients with rheumatoid arthritis","volume":"51","author":"RF Laan","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register","volume":"43","author":"G Haugeberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.53.1.18","article-title":"Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis\u2013a population based study","volume":"53","author":"H Kroger","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"ref11","first-page":"683","article-title":"Factors influencing bone loss in rheumatoid arthritis: a longitudinal study","volume":"18","author":"B Cortet","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/35.4.309","article-title":"Bone mass measurement and bone metabolism in rheumatoid arthritis: a review","volume":"35","author":"AA Deodhar","year":"1996","journal-title":"Br J Rheumatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(88)90185-7","article-title":"Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis","volume":"2","author":"JA Eastgate","year":"1988","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00002281-200307000-00016","article-title":"Effects of rheumatoid arthritis on bone","volume":"15","author":"G Haugeberg","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jbspin.2005.10.019","article-title":"Bisphosphonate therapy in rheumatoid arthritis","volume":"73","author":"V Breuil","year":"2006","journal-title":"Joint Bone Spine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/00912709922008272","article-title":"Developments in the therapeutic applications of bisphosphonates","volume":"39","author":"DL Brown","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"ref17","unstructured":"Homik J, Cranney A, Shea B, Tugwell P, Wells G, <etal>et al<\/etal>.. (2000) Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev: CD001347."},{"key":"ref18","first-page":"1539","article-title":"Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy","volume":"23","author":"G Ferraccioli","year":"1996","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(03)00208-4","article-title":"Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound","volume":"33","author":"B Frediani","year":"2003","journal-title":"Bone"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980070122","article-title":"Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients","volume":"11","author":"R Eastell","year":"2000","journal-title":"Osteoporos Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","article-title":"Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"WF Lems","year":"2006","journal-title":"Osteoporos Int"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"RN de Nijs","year":"2006","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S, Collaboration C (2008) Cochrane handbook for systematic reviews of interventions: Wiley Online Library.","DOI":"10.1002\/9780470712184"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.23988","article-title":"Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial","volume":"58","author":"T Mawatari","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1191\/0961203305lu2149oa","article-title":"Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients","volume":"14","author":"A Nzeusseu Toukap","year":"2005","journal-title":"Lupus"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"R198","DOI":"10.1186\/ar3170","article-title":"Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid","volume":"12","author":"EK Li","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"ref28","first-page":"474","article-title":"Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis","volume":"30","author":"J Hasegawa","year":"2003","journal-title":"J Rheumatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00296-005-0042-y","article-title":"Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models","volume":"26","author":"K Yamamoto","year":"2006","journal-title":"Rheumatol Int"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1479-8077.2007.00249.x","article-title":"The bone mineral density effects of calcitonin and alendronate combined therapy in patients with rheumatoid arthritis","volume":"10","author":"K Ozoran","year":"2007","journal-title":"APLAR Journal of Rheumatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002960000080","article-title":"Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids","volume":"20","author":"L Yilmaz","year":"2001","journal-title":"Rheumatol Int"},{"key":"ref32","first-page":"214","article-title":"Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study","volume":"66","author":"B Cortet","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"key":"ref33","first-page":"163","article-title":"Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases","volume":"31","author":"S Nakayamada","year":"2004","journal-title":"J Rheumatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","article-title":"Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group","volume":"83","author":"C Roux","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref35","first-page":"2424","article-title":"A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss","volume":"27","author":"JD Adachi","year":"2000","journal-title":"J Rheumatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone","volume":"16","author":"Y Boutsen","year":"2001","journal-title":"J Bone Miner Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/art.1780390307","article-title":"Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial","volume":"39","author":"F Eggelmeijer","year":"1996","journal-title":"Arthritis Rheum"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00296-004-0496-3","article-title":"The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin","volume":"26","author":"F Tascioglu","year":"2005","journal-title":"Rheumatol Int"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1248\/yakushi.127.1491","article-title":"Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients","volume":"127","author":"S Yamada","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.664647","article-title":"Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial","volume":"41","author":"M Hakala","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/03009749950154211","article-title":"The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate","volume":"28","author":"EA Jenkins","year":"1999","journal-title":"Scand J Rheumatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"JD Adachi","year":"1997","journal-title":"N Engl J Med"},{"key":"ref43","first-page":"567","article-title":"Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids","volume":"27","author":"M Benucci","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/33.4.348","article-title":"Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss","volume":"33","author":"H Mulder","year":"1994","journal-title":"Br J Rheumatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.080168","article-title":"Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy","volume":"35","author":"Y Okada","year":"2008","journal-title":"J Rheumatol"},{"key":"ref46","first-page":"2673","article-title":"Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup","volume":"30","author":"S Sato","year":"2003","journal-title":"J Rheumatol"},{"key":"ref47","first-page":"142","article-title":"Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup","volume":"35","author":"S Sato","year":"2008","journal-title":"J Rheumatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/s10165-008-0055-y","article-title":"Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol","volume":"18","author":"S Takeda","year":"2008","journal-title":"Mod Rheumatol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3899\/jrheum.080634","article-title":"A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus","volume":"35","author":"SS Yeap","year":"2008","journal-title":"J Rheumatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/art.21194","article-title":"Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients","volume":"52","author":"JR Curtis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","article-title":"Practice patterns in patients at risk for glucocorticoid-induced osteoporosis","volume":"16","author":"AC Feldstein","year":"2005","journal-title":"Osteoporos Int"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/art.22462","article-title":"Barriers in the management of glucocorticoid-induced osteoporosis","volume":"57","author":"JR Guzman-Clark","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref53","first-page":"1888","article-title":"Alendronate prevents steroid-inducedosteoporosis in patients with rheumatic diseases","volume":"88","author":"QH WANG","year":"2008","journal-title":"Natl Med J China"},{"key":"ref54","unstructured":"Cranney A, Welch V, Adachi JD, Homik J, Shea B, <etal>et al<\/etal>.. (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev: CD001983."},{"key":"ref55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies","volume":"15","author":"RN de Nijs","year":"2004","journal-title":"Osteoporos Int"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1359\/jbmr.2002.17.8.1512","article-title":"The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression","volume":"17","author":"S Amin","year":"2002","journal-title":"J Bone Miner Res"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, <etal>et al<\/etal>.. (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD001155.","DOI":"10.1002\/14651858.CD001155.pub2"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM200105313442214","article-title":"The effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"RL Goodman","year":"2001","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S8200","article-title":"Reducing hip fracture risk with risedronate in elderly women with established osteoporosis","volume":"4","author":"T Masud","year":"2009","journal-title":"Clin Interv Aging"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"IC Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref61","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"MM Luckey","year":"2003","journal-title":"Obstet Gynecol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0080890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:52:22Z","timestamp":1540201942000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0080890"}},"subtitle":[],"editor":[{"given":"Yu-Kang","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0080890","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}